Quadient: 11% Increase in Software Sales to Mail Clients in 2024 Reflects Rising Demand for Smarter, Multichannel Communications
Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, shared today that businesses are increasingly turning to digital solutions to meet rising customer expectations for modern, multichannel communication. This shift is driving tangible growth: in fiscal year 2024, Quadient recorded a record 11% increase in cross-sales of its Digital automation solutions within its Mail customer base.
This growth highlights a broader shift in customer engagement strategies, driven by evolving consumer expectations. Independent research commissioned by Quadient in fall 2024, which surveyed 6,000 consumers across the United States, United Kingdom, and France, revealed a clear demand for more modern, multichannel communication experiences. While physical mail remains relevant, a majority of respondents in each country want companies to communicate through multiple channels, including email, mail, text, mobile apps, and social media. This includes 73 percent in the USA, 66 percent in France, and 62 percent in the UK. The findings send a critical message to businesses: organizations that align their strategies with these changing preferences are better positioned to improve customer satisfaction, foster loyalty, and remain competitive in an increasingly digital marketplace.
'We're meeting our customers where they are and helping them go further,' said Alain Fairise, Chief Solution Officer, Mail Automation at Quadient. 'This isn't just about adopting new technology, it's about enabling smarter, more agile ways to connect. Consumers are not only ready for smarter digital communications, they now expect it. To stay competitive, businesses need trusted partners who can guide them through digital transformation with confidence and minimal disruption. Our growth in Digital cross-sales reflects that trust. By combining intelligent automation with proven expertise in physical communications, we're helping organizations reduce complexity, unlock growth opportunities, and build more resilient, future-ready customer relationships.'
With more than 350,000 business customers worldwide, Quadient is helping organizations across industries modernize how they communicate. Through its intelligent automation platform, including Quadient Impress and Quadient Inspire, companies are leveraging both physical and digital channels to improve efficiency, consistency, and responsiveness. In 2024, Quadient recorded its highest level of Digital solution sales into its Mail customer base, while its Mail business continued to outperform the market. Looking ahead, Quadient will continue investing in intelligent hybrid communication solutions to support businesses in delivering meaningful, future-ready customer communications. To know more about Quadient's smart mail solutions, go to https://mail.quadient.com/en/mailroom-software.
About QuadientQuadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit www.quadient.com.
Contacts
Joe Scolaro, Quadient
Sandy Armstrong, Sterling Kilgore
Global Press Relations Manager
VP of Media & Communications
+1 203-301-3673
+1-630-699-8979
j.scolaro@quadient.com
sarmstrong@sterlingkilgore.com
Attachment
PR_Mail and Digital cross-sales dynamics-EN vdef
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Cegedim : Implementation of the plan to transfer the listing of the Group's shares on Euronext Growth
PRESS RELEASE Stock market information Cegedim : Implementation of the plan to transfer the listing of the Group's shares on Euronext Growth Boulogne-Billancourt, June 13 2025 - The Combined General Meeting of shareholders of CEGEDIM S.A. held today, approved, in accordance with the provisions of Article L. 421-14 of the French Commercial Code, the proposed transfer of listing of its shares from the Euronext Paris regulated market (compartment B) to the Euronext Growth Paris multilateral trading facility, and granted full power to the Board of Directors to implement this transfer of listing. The Board of Directors, which also met today following the General Meeting, decided to implement this transfer. In the next few days, the Company will file an application with Euronext Paris for the delisting of its shares from Euronext Paris and their concomitant listing on Euronext Growth. Reasons for the transfer Such a transfer will enable CEGEDIM S.A to improve the share's visibility and attractiveness, placing it among the top 30 market capitalizations on Euronext Growth. As part of this change, the Company will move to a less-regulated market, which entails some regulatory relief, but will continue to maintain the best practices described hereafter. Main consequences of the transfer In accordance with current regulations, CEGEDIM S.A. informs its shareholders of the main possible consequences of such a transfer (non-exhaustive list): Periodic information The Company will publish, within four months of the end of the financial year, an annual report including its annual and consolidated financial statements, a management report and the reports of the statutory auditors. The Company will also publish, within four months of the end of the first half of the year, a half-yearly report including its consolidated half-yearly financial statements and a business report relating to these statements. The half-yearly financial statements no longer have to be audited by the statutory auditors. The Company will continue to publish the four quarterly revenue figures, to apply IFRS standards for the consolidated financial statements and to comply with CSRD requirements for sustainability information, the change in market having no impact on this subject. Lastly, the following information in the management report (including the corporate governance report) will no longer be required:- information relating to the remuneration of corporate officers,- information having an impact in the event of a public offer;- and the content of the corporate governance report will be streamlined. Permanent information The Company will continue to inform the public of any information likely to have a significant impact on the share price (insider information). Regulated information (and in particular insider information) must always be disseminated effectively and in full. The Company will continue to use a professional disseminator. The Company will continue to draw up lists of insiders, and senior executives and managers will continue to make declarations of securities transactions to the AMF. Composition of the Board - Corporate governance The Company will continue to apply the rules on parity on the Board set out in Article L.225-18-1 of the French Commercial Code. These parity rules are also in line with the Company's CSR commitments. The Company will continue to be subject to the legal provisions of articles L.823-19 et seq. of the French Commercial Code concerning audit committees. More generally, the existing committees will be maintained, as the Company does not wish to change its good governance practices. Executive remuneration The Shareholders' Meeting will no longer be required to approve the remuneration policy for corporate officers or to approve the remuneration paid or awarded to corporate officers in respect of the previous financial year. Shareholders' Meetings The press release specifying the terms of availability of the documents submitted to the meeting will no longer be required. The preparatory documents for the meeting and other documents (including the total number of voting rights and shares existing at the date of publication of the prior notice) will no longer be required to be posted online twenty-one days before the date of the Shareholders' Meeting, but on the date of the notice of meeting. The results of votes and the minutes of the Shareholders' Meeting will continue to be posted on the Company's website. Disclosure thresholds - Public offer The protection of minority shareholders, in the event of a change of control, will be ensured on Euronext Growth Paris by the mechanism of a mandatory public offer in the event of crossing, directly or indirectly,alone or in concert, the threshold of 50% of the capital or voting rights. Furthermore, companies listed on Euronext Growth Paris only need to communicate to the market, in terms of changes in shareholding, the crossing of thresholds (upwards or downwards) of 50% and 90% of the capital or voting rights. However, in accordance with legal provisions, the company will remain subject, for a period of 3 years from its delisting from the Euronext Paris market, to the public offer regime and the maintenance of information obligations relating to threshold crossings and declarations of intentions as applicable to companies listed on Euronext Paris. Liquidity of the share As Euronext Growth is a less-regulated market, the transfer to Euronext Growth Paris could result in a change in the liquidity of CEGEDIM S.A. shares, which could differ from the liquidity observed on the regulated Euronext Paris market. The Company confirms that the liquidity contact currently in place will be maintained after the market transfer. The transfer could also lead some investors, favoring shares of issuers listed on a regulated market, to sell their CEGEDIM S.A. shares. After studying the composition of its shareholder base, the Company has identified only a very limited number of funds whose prospectuses exclude the possibility of investing on Euronext Growth. Provisional timetable for the transaction (subject to approval by Euronext) In the coming days, an application will be filed with Euronext Paris for the delisting of Cegedim Group shares from the Euronext regulated market and their concomitant admission to Euronext Growth. Subject to approval by Euronext Paris, the Group expects to be admitted to Euronext Growth Paris in early September 2025. The Cegedim Group will be supported in its plan to transfer to Euronext Growth by TP ICAP Midcap as listing sponsor. About Cegedim:Founded in 1969, Cegedim is an innovative technology and services group in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals. Cegedim employs nearly6,700 people in more than 10 countries and generated revenue of over €654 million in 2024. Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more please visit: follow Cegedim on X: @Cegedimgroup, LinkedIn, and Facebook. Aude BalleydierCegedimMedia Relations and Communications ManagerTel.: +33 (0)1 49 09 68 Damien BuffetCegedimHead of Financial CommunicationTel.: +33 (0)7 64 63 55 Céline Pardo Becoming RP AgencyMedia Relations ConsultantTel.: +33 (0)6 52 08 13 66cegedim@ Attachment Cegedim_EuronextGrowthTransfert_postAG_ENGError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 days ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 days ago
- Yahoo
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025, on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group), on June 18, in Paris, France; International Neoantigen Summit, on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_ENSign in to access your portfolio
